Cookie Policy
Updated on: 16 October 2025
CONTENTS
- INTRODUCTION
- WHAT ARE COOKIES AND OTHER TRACKING TECHNOLOGIES?
- WHAT TYPES OF COOKIES AND SIMILAR TECHNOLOGIES ARE USED BY THIS WEBSITE AND WHAT THEY ARE USED FOR?
- MANAGING COOKIES
- YOUR RIGHTS IN RELATION TO THE PROCESSING OF YOUR PERSONAL DATA
- DATA CONTROLLER AND DATA PROTECTION OFFICER (DPO)
- CHANGES TO THIS COOKIE POLICY
INTRODUCTION
This Cookie Policy applies to the website https://prize.recordati.com (hereinafter referred to as the “Website“), managed by Recordati Industria Chimica e Farmaceutica S.p.A., with registered office in Via Matteo Civitali 1, Milan – Italy (hereinafter “Recordati“, “we“, “us“), in its capacity as data controller. The Privacy Policy of the Website is available https://prize.recordati.com/privacy-policy.
This Cookie Policy describes the use of cookies and other similar technologies within our Website. Any third-party websites accessed from this Website are not covered by this Cookie Policy.
Visitors of this Website (“you” or “User”) can set their browser not to accept cookies, as explained below in the “Manage cookies” section. When cookies are disabled, some features of our Website may not function properly.
WHAT ARE COOKIES AND OTHER TRACKING TECHNOLOGIES?
Cookies are small files sent by websites you visit, including this Website, and stored on the device you use to access them. When users visit the same website again, the browser reads the cookies stored on the device and transmits the information back to the website that originally created or installed those cookies.
Cookies are divided according to their duration into:
- session cookies, when they are automatically deleted at the end of the browsing session; and
- permanent cookies, when they remain stored on the user’s device even after the closure of the browsing session, for a time established by the creator of the cookie itself. These cookies are automatically deleted once the pre-set duration period has elapsed or alternatively they can be deleted directly by the User as indicated in the appropriate section of this Cookie Policy.
Depending on who manages them, cookies can be divided into:
- first-party cookies, when they are set and managed directly by the website manager; and
- third-party cookies, when they are managed by a domain other than the one visited by the user.
In addition, cookies are divided according to their function and purpose into:
- technical cookies, which are necessary for the operation of a website, including the provision of information society services requested by users. If strictly necessary for the use of a website, these cookies do not require the user’s prior consent and cannot be switched off. Without these cookies some services or functions could not be provided and the browsing of a website would not be easy and functional;
- analytics cookies, which are used to obtain statistical information, in an aggregate manner or not, on the number of users accessing a website and about how the website is used. Analytics cookies, where adequately anonymized, do not require the user’s prior consent to be installed; and
- profiling cookies, aimed at creating user profiles and used in order to send and show advertising messages in line with the preferences expressed by the user while browsing. Profiling cookies require the user’s prior consent.
In Italy, as established in the General Provision of the Italian Data Protection Authority of May 8, 2014 entitled “Identification of simplified procedures for the information and acquisition of consent for the use of cookies”, as updated by the Guidelines of June 8, 2021, the category of technical cookies may also include, in some circumstances, the so called analytical cookies, which are used to collect aggregate information on the number of users and how they visit a website, and then compile general statistics on the service and its use.
WHAT TYPES OF COOKIES AND SIMILAR TECHNOLOGIES ARE USED BY THIS WEBSITE AND WHAT THEY ARE USED FOR?
This Website uses technical and analytics cookies. Below is a breakdown of the cookies used by our Website according to the purpose for which they are used.
|
Name |
Source |
Purpose |
Duration |
Type |
|
.ASPXAUTH |
Website |
Authentication in order to access the personal area for the management of the alert service. |
3 hours |
Technical, first-party cookie |
|
elementor |
Website |
The website’s WordPress theme uses this cookie. It allows the website owner to implement or change the website’s content in real-time. |
Persistent |
Technical, first-party cookie |
|
pll_language |
Website |
Polylang sets this cookie to remember the language the user selects when returning to the website and get the language information when unavailable in another way. |
1 year |
Technical, first-party cookie |
|
_pk_id |
Website |
Anonymous analysis of visits and browsing performance. For further information, please refer to the third party’s privacy notice here: https://matomo.org/privacy-policy/ |
1 year 1 month |
Third party cookie analytics |
|
_pk_ses |
Website |
Anonymous analysis of visits and browsing performance. For further information, please refer to the third party’s privacy notice here: https://matomo.org/privacy-policy/ |
1 year 1 month |
Third party cookie analytics |
MANAGING COOKIES
If you wish to delete or check the cookies installed on your device, as well as to withdraw consent you may have previously provided to the use of cookies and similar technologies by this Website, you can access the relevant cookie settings via:
- your web browser settings. Here are the links you can follow for the main web browsers:
-
- Microsoft Edge https://support.microsoft.com/en-us/microsoft-edge/view-cookies-in-microsoft-edge-a7d95376-f2cd-8e4a-25dc-1de753474879
- Chrome: http://support.google.com/chrome/bin/answer.py?hl=en-GB&hlrm=nl&answer=95647
- Firefox: http://support.mozilla.org/en-US/kb/enable-and-disable-cookies-website-preferences?s=cookies&r=5&as=s
- Safari: http://support.apple.com/kb/PH5042
You can also disable cookies through the www.youronlinechoices.com/it portal.
If you disable the cookies that this Website uses, some of the features of this Website may not be displayed correctly.
YOUR RIGHTS IN RELATION TO THE PROCESSING OF YOUR PERSONAL DATA
You can exercise your rights regarding the processing of your personal data by contacting the Recordati or the Data Protection Officer (DPO) at the contact details below. For more information on your rights of access, rectification, erasure, opposition, restriction of processing and data portability, please visit our https://prize.recordati.com/privacy-policy You can also lodge a complaint with the competent supervisory authority.
DATA CONTROLLER AND DATA PROTECTION OFFICER (DPO)
The data controller is Recordati Industria Chimica e Farmaceutica S.p.A., a company of the Recordati Group, with registered office at Via Matteo Civitali 1, Milan – Italy (“Recordati” or “Data Controller” or “we”). The Data Protection Officer of the Recordati Group can be contacted for any privacy issue arising or in connection with the processing of personal data at the following email address: groupDPO@recordati.com.
CHANGES TO THIS COOKIE POLICY
This Cookie Policy may be updated over time; in this case, we will notify Users of the change to this Cookie Policy through a special banner or pop-up message on the Website.
Prof Sandra Strauss, MD PhD FRCP
Sandra Strauss is Professor of Medical and Teenage Young Adult (TYA) Oncology and a Consultant Medical Oncologist. She specialises in the systemic treatment of bone and soft tissue sarcoma and leads the clinical service at University College London Hospital, part of the London Sarcoma Service, one of the largest sarcoma services in Europe.
Her academic post is based within University College London and is focused on translational and clinical research to develop novel therapies for sarcoma patients. She has over 15 years’ experience as a chief and principal investigator for international and national clinical trials. She chairs the executive committee of the EuroEwing consortium (EEC), a pan-European collaboration that has brought together clinicians, scientists and patient advocates to improve outcome for patients with Ewing sarcoma, conducting practice-changing clinical trials with focused translational research. She chairs the UK NCRI Sarcoma Clinical Studies Group Bone Subgroup and is the current sarcoma track chair of European Society of Medical Oncology (ESMO).
She is an executive Committee member of FOSTER (Fight Osteosarcoma through European Research), a scientific committee member of SIOPE, the European Society of paediatric oncology, and ESMO rare cancer and sarcoma annual meeting.
She is an executive member of the Hibiscus Harmonization International Bone Sarcoma Consortium (HIBiSCus), a member of European Organisation for Research and Treatment of Cancer (EORTC) and Innovative Therapies for Children with Cancer (ITCC) consortium.
Dr. Alice L. Yu, M.D., Ph.D
Alice L. Yu, M.D., Ph.D. is an Academician of Academia Sinica in Taiwan. She has been a Distinguished Chair Professor of the Institute of Stem Cell & Translational Cancer Research at Chang Gung Memorial Hospital & Chang Gung University since 2013 and Professor Emeritus of Pediatrics at the University of California in San Diego.
From 2003 to May 2013, Dr. Yu served as a Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica, in Taiwan. Prior to this, she was the Chief of Pediatric Hematology Oncology at the University of California in San Diego. She has been a long-time member of the Children’s Oncology Group in the United States, serving on the Steering Committee of Neuroblastoma. She is also a member of various scientific committees and associations.
As a pioneer in cancer immunotherapy, Dr. Yu has taken an anti-GD2 monoclonal antibody (Dinutuximab) from preclinical to phase III clinical trial, culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent to target carbohydrate antigen. Treatment with anti-GD2 has since become standard of care for high risk neuroblastoma. For another prevalent tumor-associated glycan, Globo H, her group has demonstrated the adverse impact of its expression on the clinical outcome of patients with hepatoma, cholangiocarcinoma and gallbladder cancer. She has also uncovered the roles of Globo H in cancer as an immune checkpoint molecule and an angiogenic factors, providing rationales for the development of Globo H-targeted immunotherapeutics.
She received the Lifetime Achievement Award from the Advances in Neuroblastoma Research Association in 2025, Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020, Excellence in Technology Transfer Award from Federal Laboratory Consortium, USA in 2016, The 55th Academic Award from the Ministry of Education, The 19th Wang Min-Ning Memorial Award for Outstanding Contribution to the Development Medical Science and Technology, National Health and Society, Year 2000 “Key to Life” Award from Leukemia & Lymphoma Society, USA, etc.
Prof. Robert J. Desnick
Dean for Genetics and Genomic Medicine, Professor and Chairman Emeritus of the Department of Genetics and Genomic Sciences, The Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Robert J. Desnick is Dean for Genetic and Genomic Medicine and Professor and Chairman Emeritus of the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai.
In 1977, he joined the Mount Sinai faculty as the Arthur J. and Nellie Z. Cohen Professor of Pediatrics and Genetics, and Chief of Medical and Molecular Genetics. From 1993-2011, he was the first Chairman of the Department of Genetics and Genomic Sciences at Mount Sinai. In 2011 he became the Dean for Genetics and Genomic Medicine.
Dr. Desnick’s research interests include lysosomal storage diseases (LSDs) and the inborn errors of heme biosynthesis, the porphyrias, and in particular, their treatment.
His research efforts led to the Federal Drugs Administration (FDA) – and European Medicine Agency (EMA) – approval of enzyme replacement therapy (ERT) for Fabry disease (Fabrazyme) and on-going ERT clinical trials (FDA “Breakthrough” status) for Niemann- Pick B disease, both in partnership with Genzyme. In addition, he was a scientific founder of Amicus Therapeutics (NASDAQ; FOLD), which is developing oral pharmacologic chaperone therapy for Fabry disease (EMA-approved in 2016), Pompe disease, and other disorders. Currently, his laboratory is using gene editing technology to engineer gene therapy in the mouse model of Fabry disease with Sangamo Therapeutics.
Arrigo Recordati
Arrigo Recordati believed research was the most powerful asset for the pharmaceutical industry. He became head of the family business in 1951, at the age of 23, and transformed the family pharmaceutical laboratory employing 325 people into an international company listed since 1984 on the Italian Stock Exchange.
Arrigo Recordati’s remarkable life came to a premature end at the age of 71, in 1999.
Under his direction, in 1953 the company’s headquarters and pharmaceutical plant moved from Correggio, a small town in the Emilia region of Italy, to Milan, the capital of Italian business. During this time Arrigo Recordati provided the company with a stronger competitive advantage by updating its research facilities with advanced pharmacological laboratories.
In the 1950s and 60s, Arrigo Recordati relied on two strong beliefs: scientific research and internationalization. To maximize the results of Recordati research, he established subsidiaries in Brazil and Mexico. Arrigo Recordati also fostered a close relationship with the United States, signing among other things a strategic partnership agreement with Syntex Corporation (acquired by Roche Corporation in 1990) – at that time a company involved in cutting-edge research on the synthesis of steroid hormones.
Arrigo Recordati strongly believed in the power of scientific research to drive the growth of the pharmaceutical industry and provide products beneficial to public health and individual well-being. Efloxate (1955), a coronary vasodilator for the treatment of cardiovascular disease, was the first compound to originate from Recordati’s research laboratories during Arrigo Recordati’s leadership. Other original molecules developed and marketed during his leadership include: dimefline (1958), a respiratory analeptic, flavoxate (1957), a urinary antispasmodic, tibezonium iodide (1971), an oral antiseptic, fenticonazole (1978), an antimycotic and lercanidipine (1984), a calcium channel blocker for the treatment of hypertension. In particular, flavoxate was the first original New Chemical Entity developed by an Italian company to be approved by FDA (Federal Drug Administration) in the United States.
Arrigo Recordati also believed that even small companies – if managed with vigor and imagination – can compete effectively in the pharmaceutical arena. In 1984 Recordati was listed on the Italian Stock Exchange, completing its transformation from a small, family-run operation to a modern, professional, publicly listed company.
After 48 years of intense and challenging leadership, Arrigo Recordati passed away, leaving a solid, international business projected into the future.